Initiator Pharma

Initiator Pharma is a Danish biopharmaceutical company focused on discovering and developing drug candidates for central nervous system disorders with significant unmet medical needs. The company advances selected programs through early clinical development and then seeks to outlicense them to larger pharmaceutical partners for later-stage development and commercialization.

— Initiator Pharma
	%
Drug discovery and early development	70% Identification and advancement of novel drug candidates for CNS disorders through preclinical and early clinical stages.
Clinical Proof-of-Concept programs	20% Focused clinical studies designed to generate value inflection points for partnering decisions.
Outlicensing and partnering	10% Transfer of development assets to pharmaceutical partners in exchange for upfront, milestone, and royalty economics.

Initiator Pharma does not sell finished medicines directly to patients; its primary counterparties are pharmaceutical...

Pharmaceutical licensing partnersprimary
Buy or license development assets to continue late-stage clinical work and commercialization.
Patients with CNS disordersprimary
Ultimate end users of the therapies the company is developing, especially in unmet-need indications.
Contract Research Organizationssecondary
Provide outsourced development, regulatory, and trial execution services that enable the virtual model.

Initiator Pharma is headquartered in Copenhagen, Denmark and is listed on Nasdaq First North Growth Market Stockholm...

•Headquartered in Copenhagen, Denmark
•Listed on Nasdaq First North Growth Market Stockholm
•Operates through outsourced CRO and partner networks
•International development spending creates currency exposure

The company’s strategy is to identify promising CNS drug candidates in late preclinical and early clinical stages and...

Advance drug candidates to Proof-of-Conceptshort-term

Clinical data is needed to validate the asset and attract partnering interest.

Secure pharma partnershipsmedium-term

Outlicensing is the core commercialization path and the main route to future economics.

Maintain a flexible virtual operating modellong-term

Outsourcing reduces fixed cost burden and allows the company to scale programs selectively.

The business is exposed to clinical, regulatory, patent, and partnering risk because value depends on successful drug...

critical

Financing dependence

R&D consumes cash before any product revenue is generated, so external capital is needed.

Scope: Company-wide
Materiality: high

high

Clinical development failure

Drug candidates may not show sufficient efficacy or safety in Proof-of-Concept studies.

Scope: Pipeline programs
Materiality: high

high

Partnering and collaboration risk

The business model depends on finding pharma partners at the right time and on acceptable terms.

Scope: Outlicensing programs
Materiality: high

high

Patent and intellectual property risk

Protection of drug candidates is essential for future licensing value and market exclusivity.

Scope: Pipeline IP
Materiality: high

medium

Currency risk

Development costs are partly incurred in international currencies, creating exchange-rate volatility.

Scope: Outsourced R&D spend
Materiality: medium

Research and development expense recognition

Affects operating loss and comparability across periods

Intangible assets and impairment

Affects balance sheet carrying values and earnings

Share-based payments and warrants

Affects equity, EPS, and diluted share count

Foreign currency translation

Affects expenses, liabilities, and cash flow presentation

Initiator Pharma

Financing dependence

Clinical development failure

Partnering and collaboration risk

Patent and intellectual property risk

Currency risk

Inhibikase Therapeutics, Inc.

Connect Biopharma Holdings Ltd

CalciMedica, Inc.

Inhibitor Therapeutics, Inc.

IMMUNIC, INC.

ArriVent BioPharma, Inc.